Tenderwize
Wróć do wyszukiwania

Open-House-Biologika-Rabattverträge 2025-15

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2027 · 339 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-15

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated value or volume guarantee; actual revenue depends on market uptake and prescribing behavior.

The contract terminates automatically at the end of the month in which patent or market exclusivity expires, potentiall...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Supply of Trastuzumab (subcutaneous injection) under a discount contract with German statutory health insurance funds.
  • Conclusion of a framework-type agreement without volume commitment; no exclusivity for any contractor.
Pokaż pełne podsumowanie

Open-House procedure by German health insurance funds (led by Techniker Krankenkasse) for discount contracts on Trastuzumab (subcutaneous injection). The procedure is open to all eligible pharmaceutical entrepreneurs throughout the contract term (max. 24 months, 01.08.2025 – 31.07.2027). No estimated contract value is provided; the procedure is not a public procurement subject to EU procurement law but a voluntary publication. Participation is possible at any time during the contract term, with specific deadlines for inclusion in the monthly pharmacy software update.

Ryzyka

No estimated value or volume guarantee; actual revenue depends on market uptake and prescribing behavior.

The contract terminates automatically at the end of the month in which patent or market exclusivity expires, potentiall...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as per § 4 Abs. 18 AMG for the specific drug.
  • Must have a valid marketing authorization for Trastuzumab (subcutaneous injection) in Germany.

Eligibility

  • Must provide a self-declaration confirming eligibility and reliability.

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria applicable; all eligible participants who meet the conditions and provide the required self-declaration are accepted.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-House-Biologika-Rabattverträge 2025-15

Single lot covering discount contracts for Trastuzumab (subcutaneous injection). All eligible pharmaceutical entrepreneurs can conclude a contract under uniform conditions; no exclusivity is granted. The contract ends at the latest on 31.07.2027, or earlier upon patent expiry/market exclusivity loss.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Jul 2025 - Jul 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria applicable; all eligible participants who meet the conditions and provide the required self-declaration are accepted.

Termin

Deadline Jul 30, 2027

Szczegóły zamówienia

Data publikacji
19 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
323734-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3